In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

Johnson & Johnson (NYSE: JNJ) has announced promising results from its pivotal Phase 3 Vivacity-MG3 study evaluating ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang, China Introduction: Efgartigimod has been approved for the treatment of acetylcholine receptor ...

“We welcome the FDA’s decision to grant Priority Review for the treatment of generalized myasthenia gravis, which underscores the need for additional treatment options in a broad population of people ...

Medications for myasthenia gravis (MG) can include cholinesterase ... They tend to work quickly and have fewer long-term side effects than corticosteroids or immunosuppressants.

Inebilizumab is under clinical development by Amgen and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase III drugs for Myasthenia Gravis have a 70% phase transition success ...

International consensus guidance and Japanese clinical guidelines for myasthenia gravis (MG) recommend achieving minimal ... the Japan Blood Products Organization, and Asahi Kasei Medical. HM has ...